Blood Coagulation Disorders  >>  Optivate (factor VIII/von Willebrand factor)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

6 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Optivate (factor VIII/von Willebrand factor) / Bio Products Lab
NCT02250482: An Open Study to Investigate the Safety and Efficacy of Optivate® in Haemophilia A Patients Undergoing Surgery.

Completed
3
Europe
Optivate® (Human Coagulation Factor VIII)
Bio Products Laboratory
Haemophilia A
08/03
 
NCT02246881: A Study to Compare the Pharmacokinetics and Safety of Current Factor VIII Concentrate and Optivate® in Haemophilia A.

Completed
3
Europe
Optivate® (Human Coagulation Factor VIII)
Bio Products Laboratory
Von Willebrand Disease
01/04
 
NCT02246868: An Open Study to Investigate the Safety and Efficacy of Optivate® in Severe Haemophilia A Patients.

Completed
3
Europe
Optivate® (Human Coagulation Factor VIII)
Bio Products Laboratory
Haemophilia A
08/04
 
NCT02246894: A Study to Investigate the Safety and Efficacy of Optivate® in Children Under 6 Years of Age With Haemophilia A.

Completed
3
Europe
Optivate® (Human Coagulation Factor VIII)
Bio Products Laboratory
Haemophilia A
01/05
 
NCT00387192 / 2006-000663-28: A Study With OPTIVATE® in People With Von Willebrand Disease

Terminated
3
26
Europe, RoW
Optivate
Bio Products Laboratory
Von Willebrand Disease
 
09/08
NCT00404300 / 2006-000664-85: Optivate in People With Von Willebrand Disease Undergoing Surgery

Terminated
3
25
Europe, RoW
Optivate
Bio Products Laboratory
Von Willebrand Disease
 
09/08

Download Options